Trump's Stock Moves in Eli Lilly: Ethics and Healthcare Implications
Earlier this year, information emerged about Donald Trump making significant stock purchases in Eli Lilly, a pharmaceutical company known for its obesity drugs. This occurred during a period when government initiatives were favorably impacting the company's business. On May 14, the federal government released ethics disclosures detailing stock and bond trades conducted on Trump's behalf between January and March 2026. These investments spanned various sectors, including tech companies, aerospace firms, and popular retail brands.
In the healthcare sector, Trump's investment in Eli Lilly is particularly notable due to concurrent regulatory developments. Government actions aligned with Eli Lilly's business interests, specifically the advancement of Medicare reimbursement for certain obesity medications, such as GLP-1 drugs. The Centers for Medicare & Medicaid Services proposed a pilot program designed to provide Medicare beneficiaries with access to these medications at a reduced cost.
The ethics disclosure forms reveal a series of stock purchases marked by ranges rather than specific amounts, with some trades noted as unsolicited. It remains uncertain if Trump personally directed any of these trades, as his assets are managed by a trust overseen by his children. Eric Trump has publicly stated that neither he nor any family member influences specific investment decisions.
Eli Lilly, which reported significant financial growth in 2025 with revenue reaching $65 billion, continues to thrive partly due to its obesity treatment portfolio. Analysts predict that expanded Medicare coverage anticipated later this year could substantially impact future revenue projections. Furthermore, Eli Lilly has been involved in programs to expand medication access for Medicare and Medicaid recipients, crucial given Medicare's historical lack of coverage for obesity drugs.
Additional regulatory actions impacting Eli Lilly include FDA decisions such as the approval of its weight-loss pill under a priority program aimed at expediting drug approvals. Despite these advancements, some FDA scrutiny persists, as the company must provide further safety data on potential liver toxicity for one of its products.
Eli Lilly and related companies have opted not to comment on these stock transactions or regulatory outcomes. Meanwhile, a White House spokesperson directed inquiries to the Trump Organization, which has yet to respond. The intersection of stock market activity and favorable regulatory actions has raised questions among ethics experts about potential conflicts of interest, prompting discussions on the need for clearer legislative guidelines regarding stock trading by sitting presidents.